Topical Management of Atopic Dermatitis and Psoriasis: Clinical Insights for Pediatricians and Dermatology Providers: PEDS23 Seminar-in-Depth
CME Seminar in Depth - May 6, 2023 10:25 AM EST
Topical Management of Atopic Dermatitis and Psoriasis: Clinical Insights for Pediatricians and Dermatology Providers
This activity is supported by educational grants from Arcuits, Dermavant, and Incyte.
At the completion of this activity, participants should be better able to:
Identify challenges associated with the use of topical corticosteroids in patients with AD and psoriasis
2Review nonsteroid topical agents for the treatment of AD and psoriasis
Discuss clinical considerations for dermatology providers and pediatricians who prescribe topical therapies to patients with AD and psoriasis
Lawrence Eichenfield, MD
Professor of Dermatology and Pediatrics
Vice-Chair, Department of Dermatology
Chief, Pediatric and Adolescent Dermatology
University of California, San Diego and Rady Children’s Hospital
San Diego, CA
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: Abbvie, Arcutis, Castle, Dermavant, Galderma, Incyte, Pfizer, Target
Consultant: AbbVie, Almirall, Arena, Aslan, Dermavant, Eli Lilly, Forte, Galderma, Incyte,Krystal, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, UCB and Ortho Derm
Speakers’ Bureau or Honoraria: Leo, Incyte, Pfizer, Regeneron, Sanofi
Ownership Interest: Forte (Board of Directors-options); Verrica: Board of Directors (options)
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.